aveo-10q_20200630.htm
false Q2 0001325879 --12-31 Accelerated Filer 0.10 true 0.10 0.2 0.066 2016-03-31 P1Y P1Y 0 0 P5Y P1Y6M P1Y3M P1Y P7Y9M14D P6Y2M4D 1.0062 0.9572 1.0477 0.9623 P5Y6M P5Y6M P6Y3M P6Y3M 0.0044 0.0057 0.0194 0.9437 0.8827 P5Y6M P5Y6M 1.0477 0.9623 P6Y3M P6Y3M 0.0044 0.0194 0.0167 0.0255 0001325879 2020-01-01 2020-06-30 xbrli:shares 0001325879 2020-08-07 iso4217:USD 0001325879 2020-06-30 0001325879 2019-12-31 iso4217:USD xbrli:shares 0001325879 us-gaap:LicenseAndServiceMember 2020-04-01 2020-06-30 0001325879 us-gaap:LicenseAndServiceMember 2019-04-01 2019-06-30 0001325879 us-gaap:LicenseAndServiceMember 2020-01-01 2020-06-30 0001325879 us-gaap:LicenseAndServiceMember 2019-01-01 2019-06-30 0001325879 us-gaap:RoyaltyMember 2020-04-01 2020-06-30 0001325879 us-gaap:RoyaltyMember 2019-04-01 2019-06-30 0001325879 us-gaap:RoyaltyMember 2020-01-01 2020-06-30 0001325879 us-gaap:RoyaltyMember 2019-01-01 2019-06-30 0001325879 2020-04-01 2020-06-30 0001325879 2019-04-01 2019-06-30 0001325879 2019-01-01 2019-06-30 0001325879 us-gaap:CommonStockMember 2019-12-31 0001325879 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001325879 us-gaap:RetainedEarningsMember 2019-12-31 0001325879 us-gaap:AdditionalPaidInCapitalMember aveo:EquityClassifiedAwardsMember 2020-01-01 2020-03-31 0001325879 aveo:EquityClassifiedAwardsMember 2020-01-01 2020-03-31 0001325879 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001325879 2020-01-01 2020-03-31 0001325879 us-gaap:CommonStockMember 2020-03-31 0001325879 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001325879 us-gaap:RetainedEarningsMember 2020-03-31 0001325879 2020-03-31 0001325879 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001325879 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001325879 us-gaap:AdditionalPaidInCapitalMember aveo:EquityClassifiedAwardsMember 2020-04-01 2020-06-30 0001325879 aveo:EquityClassifiedAwardsMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001325879 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001325879 us-gaap:CommonStockMember 2020-06-30 0001325879 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001325879 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001325879 us-gaap:RetainedEarningsMember 2020-06-30 0001325879 aveo:SVBLeerinkMember 2019-01-01 2019-03-31 0001325879 aveo:PublicOfferingMember 2019-04-01 2019-06-30 0001325879 aveo:PublicOfferingMember 2020-04-01 2020-06-30 0001325879 us-gaap:CommonStockMember 2018-12-31 0001325879 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001325879 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001325879 us-gaap:RetainedEarningsMember 2018-12-31 0001325879 2018-12-31 0001325879 us-gaap:CommonStockMember aveo:SVBLeerinkMember 2019-01-01 2019-03-31 0001325879 us-gaap:AdditionalPaidInCapitalMember aveo:SVBLeerinkMember 2019-01-01 2019-03-31 0001325879 us-gaap:AdditionalPaidInCapitalMember aveo:EquityClassifiedAwardsMember 2019-01-01 2019-03-31 0001325879 aveo:EquityClassifiedAwardsMember 2019-01-01 2019-03-31 0001325879 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001325879 2019-01-01 2019-03-31 0001325879 us-gaap:CommonStockMember 2019-03-31 0001325879 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001325879 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001325879 us-gaap:RetainedEarningsMember 2019-03-31 0001325879 2019-03-31 0001325879 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001325879 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001325879 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001325879 us-gaap:CommonStockMember 2019-06-30 0001325879 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001325879 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001325879 us-gaap:RetainedEarningsMember 2019-06-30 0001325879 2019-06-30 0001325879 aveo:PIPEWarrantsMember 2020-01-01 2020-06-30 aveo:Subsidiary 0001325879 aveo:KyowaKirinMember us-gaap:SubsequentEventMember 2020-08-02 2020-08-02 0001325879 aveo:AmendedAndRestatedLoanAndSecurityAgreementMember aveo:FoodAndDrugAdministrationMarketingApprovalMember us-gaap:SubsequentEventMember 2020-08-05 2020-08-07 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:PotentialMarketingApprovalCountryGroupOneMember 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:PotentialMarketingApprovalCountryGroupTwoMember 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember srt:MaximumMember 2020-06-30 xbrli:pure 0001325879 aveo:KyowaHakkoKirinMember 2020-01-01 2020-06-30 0001325879 2020-02-19 2020-02-19 0001325879 2020-02-01 2020-02-29 0001325879 aveo:EUSAPharmaUKLimitedMember 2020-04-01 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember 2019-04-01 2019-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember 2020-01-01 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember 2019-01-01 2019-06-30 utr:sqft 0001325879 2020-03-05 iso4217:USD utr:sqft 0001325879 2020-03-05 2020-03-05 0001325879 us-gaap:PrivatePlacementMember aveo:PIPEWarrantsMember 2016-05-31 0001325879 us-gaap:PrivatePlacementMember aveo:PIPEWarrantsMember 2020-06-30 0001325879 us-gaap:PrivatePlacementMember aveo:PIPEWarrantsMember 2020-01-01 2020-06-30 0001325879 aveo:PIPEWarrantsMember 2020-06-30 0001325879 aveo:PIPEWarrantsMember 2020-04-01 2020-06-30 0001325879 aveo:PIPEWarrantsMember 2020-01-01 2020-06-30 0001325879 aveo:PIPEWarrantsMember 2019-04-01 2019-06-30 0001325879 aveo:PIPEWarrantsMember 2019-01-01 2019-06-30 0001325879 aveo:PIPEWarrantsMember 2019-12-31 0001325879 aveo:PIPEWarrantsMember 2020-01-01 2020-03-31 0001325879 aveo:PIPEWarrantsMember 2020-03-31 0001325879 aveo:PIPEWarrantsMember 2020-04-01 2020-06-30 0001325879 aveo:PIPEWarrantsMember 2020-06-30 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2016-05-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2020-06-30 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2016-05-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2020-03-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2020-06-30 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2016-05-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-06-30 0001325879 aveo:PIPEWarrantsMember 2016-05-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2016-05-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-03-31 0001325879 aveo:PIPEWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-06-30 0001325879 srt:MinimumMember 2020-01-01 2020-06-30 0001325879 aveo:CashAndMoneyMarketFundsMember 2020-06-30 0001325879 aveo:CashAndMoneyMarketFundsMember 2019-12-31 0001325879 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001325879 us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0001325879 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember aveo:CashAndMoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember aveo:CashAndMoneyMarketFundsMember 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember aveo:PIPEWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-06-30 0001325879 us-gaap:FairValueMeasurementsRecurringMember aveo:PIPEWarrantsMember 2020-06-30 0001325879 us-gaap:FairValueInputsLevel1Member aveo:CashAndMoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001325879 aveo:CashAndMoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001325879 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001325879 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001325879 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001325879 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001325879 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001325879 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember aveo:PIPEWarrantsMember 2019-12-31 0001325879 us-gaap:FairValueMeasurementsRecurringMember aveo:PIPEWarrantsMember 2019-12-31 0001325879 aveo:PIPEWarrantsMember 2020-06-30 0001325879 aveo:PIPEWarrantsMember 2019-06-30 0001325879 aveo:OfferingWarrantsMember 2020-06-30 0001325879 aveo:OfferingWarrantsMember 2019-06-30 0001325879 aveo:SettlementWarrantsMember 2019-06-30 0001325879 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001325879 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001325879 aveo:OfferingWarrantsMember 2020-01-01 2020-06-30 0001325879 aveo:OfferingWarrantsMember 2019-01-01 2019-06-30 0001325879 aveo:PIPEWarrantsMember 2020-01-01 2020-06-30 0001325879 aveo:PIPEWarrantsMember 2019-01-01 2019-06-30 0001325879 aveo:SettlementWarrantsMember 2019-01-01 2019-06-30 0001325879 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001325879 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001325879 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001325879 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001325879 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001325879 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001325879 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001325879 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001325879 2019-01-01 2019-12-31 aveo:Segment 0001325879 country:US 2020-01-01 2020-06-30 0001325879 us-gaap:NonUsMember 2020-06-30 0001325879 us-gaap:ResearchAndDevelopmentExpenseMember aveo:AstraZenecaMember aveo:AstraZenecaAgreementMember 2020-04-01 2020-06-30 0001325879 us-gaap:ResearchAndDevelopmentExpenseMember aveo:AstraZenecaMember aveo:AstraZenecaAgreementMember 2019-04-01 2019-06-30 0001325879 us-gaap:ResearchAndDevelopmentExpenseMember aveo:AstraZenecaMember aveo:AstraZenecaAgreementMember 2020-01-01 2020-06-30 0001325879 us-gaap:ResearchAndDevelopmentExpenseMember aveo:AstraZenecaMember aveo:AstraZenecaAgreementMember 2019-01-01 2019-06-30 0001325879 aveo:AstraZenecaMember aveo:AstraZenecaAgreementMember 2020-06-30 0001325879 aveo:CANbridgeLifeSciencesLtdMember 2020-01-01 2020-06-30 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember 2016-04-01 2016-04-30 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember 2016-04-30 aveo:Installment 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember 2020-01-01 2020-06-30 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember 2017-03-01 2017-03-31 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember 2017-09-01 2017-09-30 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember aveo:DevelopmentAndRegulatoryMilestoneEventsMember 2018-08-01 2018-08-31 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember aveo:AdditionalDevelopmentAndRegulatoryMilestoneEventsMember 2020-01-01 2020-06-30 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember aveo:CommercialMilestoneMember 2020-01-01 2020-06-30 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember aveo:DevelopmentAndRegulatoryMilestoneEventsMember 2018-08-01 2018-08-31 0001325879 aveo:CANbridgeLifeSciencesLtdMember 2018-08-01 2018-08-31 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember 2016-03-01 2016-03-31 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember 2017-01-01 2017-12-31 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember 2018-07-01 2018-09-30 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember us-gaap:LicenseAndServiceMember 2018-07-01 2018-09-30 0001325879 aveo:CANbridgeLifeSciencesLtdMember us-gaap:LicensingAgreementsMember 2018-09-30 0001325879 aveo:EUSAPharmaUKLimitedMember 2015-01-01 2015-12-31 0001325879 aveo:EUSAPharmaUKLimitedMember 2017-09-01 2017-09-30 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:TiNivoTrialMember 2017-10-01 2017-10-31 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:OptInToPlannedPhaseThreeStudyMember 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:MilestoneUKReimbursementApprovalMember 2018-03-01 2018-03-31 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:MilestoneGermanReimbursementApprovalMember 2018-12-01 2018-12-31 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:MilestoneSpainReimbursementApprovalMember 2019-05-01 2019-05-31 aveo:Indication 0001325879 aveo:EUSAPharmaUKLimitedMember 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember 2018-02-01 2018-02-28 0001325879 aveo:EUSAPharmaUKLimitedMember 2018-11-01 2018-11-30 0001325879 aveo:EUSAPharmaUKLimitedMember 2019-02-01 2019-02-28 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:MilestoneUKReimbursementApprovalMember 2018-04-01 2018-04-30 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:MilestoneGermanReimbursementApprovalMember 2019-01-01 2019-01-31 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:MilestoneSpainReimbursementApprovalMember 2019-06-01 2019-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember us-gaap:RoyaltyMember 2020-04-01 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember us-gaap:RoyaltyMember 2019-04-01 2019-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember us-gaap:RoyaltyMember 2020-01-01 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember us-gaap:RoyaltyMember 2019-01-01 2019-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember 2018-01-01 2018-03-31 0001325879 aveo:EUSAPharmaUKLimitedMember 2015-12-01 2018-02-28 0001325879 aveo:EUSAPharmaUKLimitedMember 2018-02-28 0001325879 aveo:EUSAPharmaUKLimitedMember 2018-10-01 2018-12-31 0001325879 aveo:EUSAPharmaUKLimitedMember 2015-12-01 2018-11-30 0001325879 aveo:EUSAPharmaUKLimitedMember 2018-11-30 0001325879 aveo:EUSAPharmaUKLimitedMember 2019-01-01 2019-03-31 0001325879 aveo:EUSAPharmaUKLimitedMember 2015-12-01 2019-02-28 0001325879 aveo:EUSAPharmaUKLimitedMember 2019-02-28 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:UpfrontPaymentMember aveo:EUSAPharmaUKLimitedMember 2020-01-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:ResearchAndDevelopmentPaymentEMAApprovalInRCCMember aveo:EUSAPharmaUKLimitedMember 2020-01-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:MilestoneUKReimbursementApprovalMember aveo:EUSAPharmaUKLimitedMember 2020-01-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:MilestoneGermanReimbursementApprovalMember aveo:EUSAPharmaUKLimitedMember 2020-01-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:MilestoneSpanishReimbursementApprovalMember aveo:EUSAPharmaUKLimitedMember 2020-01-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:UpfrontPaymentMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:UpfrontPaymentMember 2019-04-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:ResearchAndDevelopmentPaymentEMAApprovalInRCCMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:ResearchAndDevelopmentPaymentEMAApprovalInRCCMember 2019-04-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:MilestoneUKReimbursementApprovalMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:MilestoneUKReimbursementApprovalMember 2019-04-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:MilestoneGermanReimbursementApprovalMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:MilestoneGermanReimbursementApprovalMember 2019-04-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:MilestoneSpanishReimbursementApprovalMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:MilestoneSpanishReimbursementApprovalMember 2019-04-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:CollaborationAndLicensingMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:CollaborationAndLicensingMember 2019-04-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember us-gaap:RoyaltyMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember us-gaap:RoyaltyMember 2019-04-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember 2019-04-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:UpfrontPaymentMember 2019-01-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:ResearchAndDevelopmentPaymentEMAApprovalInRCCMember 2019-01-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:MilestoneUKReimbursementApprovalMember 2019-01-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:MilestoneGermanReimbursementApprovalMember 2019-01-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:MilestoneSpanishReimbursementApprovalMember 2019-01-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:CollaborationAndLicensingMember 2020-01-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember aveo:CollaborationAndLicensingMember 2019-01-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember us-gaap:RoyaltyMember 2020-01-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember us-gaap:RoyaltyMember 2019-01-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember 2020-01-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember 2019-01-01 2019-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member us-gaap:AccountsReceivableMember aveo:EUSAPharmaUKLimitedMember 2019-12-31 0001325879 us-gaap:AccountingStandardsUpdate201409Member us-gaap:AccountsReceivableMember aveo:EUSAPharmaUKLimitedMember 2020-04-01 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member us-gaap:AccountsReceivableMember aveo:EUSAPharmaUKLimitedMember 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:UpfrontPaymentMember aveo:EUSAPharmaUKLimitedMember 2019-12-31 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:ResearchAndDevelopmentPaymentEMAApprovalInRCCMember aveo:EUSAPharmaUKLimitedMember 2019-12-31 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:MilestoneUKReimbursementApprovalMember aveo:EUSAPharmaUKLimitedMember 2019-12-31 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:MilestoneGermanReimbursementApprovalMember aveo:EUSAPharmaUKLimitedMember 2019-12-31 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:MilestoneSpanishReimbursementApprovalMember aveo:EUSAPharmaUKLimitedMember 2019-12-31 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember 2019-12-31 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:UpfrontPaymentMember aveo:EUSAPharmaUKLimitedMember 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:ResearchAndDevelopmentPaymentEMAApprovalInRCCMember aveo:EUSAPharmaUKLimitedMember 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:MilestoneUKReimbursementApprovalMember aveo:EUSAPharmaUKLimitedMember 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:MilestoneGermanReimbursementApprovalMember aveo:EUSAPharmaUKLimitedMember 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:MilestoneSpanishReimbursementApprovalMember aveo:EUSAPharmaUKLimitedMember 2020-06-30 0001325879 us-gaap:AccountingStandardsUpdate201409Member aveo:EUSAPharmaUKLimitedMember 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:TiNivoTrialMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:TiNivoTrialMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:TiNivoTrialMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:TiNivoTrialMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:TiNivoTrialMember 2020-06-30 0001325879 us-gaap:LicenseAndServiceMember aveo:NovartisMember 2019-01-01 2019-01-31 0001325879 us-gaap:LicenseAndServiceMember aveo:NovartisMember 2018-08-28 2018-08-28 0001325879 aveo:BiodesixMember aveo:FOCALStudyMember 2014-04-30 0001325879 aveo:BiodesixMember aveo:FOCALTrialMember 2014-04-30 0001325879 aveo:BiodesixMember aveo:FOCALTrialMember 2020-04-01 2020-06-30 0001325879 aveo:BiodesixMember aveo:FOCALTrialMember 2019-04-01 2019-06-30 0001325879 aveo:BiodesixMember aveo:FOCALTrialMember 2020-01-01 2020-06-30 0001325879 aveo:BiodesixMember aveo:FOCALTrialMember 2019-01-01 2019-06-30 0001325879 aveo:BiodesixMember 2020-06-30 0001325879 aveo:BiogenIdecInternationalGmbHMember srt:MaximumMember 2020-01-01 2020-06-30 0001325879 aveo:BiogenIdecInternationalGmbHMember us-gaap:LicensingAgreementsMember aveo:DevelopmentAndRegulatoryMilestoneEventsMember 2018-08-01 2018-08-31 0001325879 aveo:BiogenIdecInternationalGmbHMember 2018-10-01 2018-10-31 0001325879 aveo:StVincentHospitalSydneyLimitedMember 2020-01-01 2020-06-30 0001325879 aveo:StVincentHospitalSydneyLimitedMember us-gaap:LicensingAgreementsMember 2020-01-01 2020-06-30 0001325879 aveo:StVincentHospitalSydneyLimitedMember aveo:DevelopmentAndRegulatoryMilestoneEventsMember srt:MaximumMember 2020-06-30 0001325879 aveo:StVincentHospitalSydneyLimitedMember 2017-02-28 0001325879 aveo:StVincentHospitalSydneyLimitedMember 2017-03-01 2017-03-31 0001325879 aveo:StVincentHospitalSydneyLimitedMember 2019-01-01 2019-01-31 0001325879 aveo:StVincentHospitalSydneyLimitedMember 2019-01-31 0001325879 aveo:KKCAgreementMember us-gaap:LicensingAgreementsMember 2019-09-01 2019-09-30 0001325879 aveo:KKCAgreementMember us-gaap:LicensingAgreementsMember 2019-08-31 0001325879 aveo:KKCAgreementMember us-gaap:LicensingAgreementsMember 2020-01-01 2020-06-30 0001325879 aveo:KKCAgreementMember us-gaap:LicensingAgreementsMember 2010-03-01 2010-03-31 0001325879 aveo:KyowaKirinMember us-gaap:LicensingAgreementsMember aveo:FoodAndDrugAdministrationMarketingApprovalMember 2012-12-01 2012-12-31 0001325879 aveo:KKCAgreementMember 2020-06-30 0001325879 aveo:KyowaKirinMember us-gaap:LicensingAgreementsMember 2020-06-30 0001325879 aveo:KyowaKirinMember aveo:OptInToPlannedPhaseThreeStudyMember srt:MaximumMember 2006-12-01 2006-12-31 0001325879 aveo:EUSAPharmaUKLimitedMember 2015-12-01 2015-12-31 0001325879 aveo:EUSAPharmaUKLimitedMember aveo:OptInToCoDevelopTiNivoTrialMember 2017-09-01 2017-09-30 0001325879 aveo:KyowaKirinMember us-gaap:LicensingAgreementsMember 2006-12-01 2006-12-31 0001325879 aveo:KyowaKirinMember us-gaap:LicensingAgreementsMember 2020-01-01 2020-06-30 0001325879 aveo:KyowaKirinMember us-gaap:LicensingAgreementsMember aveo:InvestigationalNewDrugMarketingApprovalMember us-gaap:SubsequentEventMember 2020-08-02 2020-08-02 0001325879 aveo:KyowaKirinMember 2019-07-01 2019-09-30 0001325879 aveo:KyowaKirinMember 2019-09-01 2019-09-30 0001325879 aveo:HerculesAmendedLoanAgreementMember us-gaap:LoansPayableMember 2014-09-01 2014-09-30 0001325879 aveo:HerculesAmendedLoanAgreementMember us-gaap:LoansPayableMember 2020-01-01 2020-06-30 0001325879 aveo:HerculesAmendedLoanAgreementMember us-gaap:LoansPayableMember 2020-06-30 0001325879 aveo:HerculesMayTwoThousandSixteenLoanAgreementMember us-gaap:LoansPayableMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-05-01 2016-05-31 0001325879 aveo:HerculesMayTwoThousandSixteenLoanAgreementMember us-gaap:LoansPayableMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-06-01 2017-06-30 0001325879 aveo:HerculesMayTwoThousandSixteenLoanAgreementMember us-gaap:LoansPayableMember 2016-05-01 2016-05-31 0001325879 aveo:HerculesMayTwoThousandSixteenLoanAgreementMember us-gaap:LoansPayableMember 2017-06-30 0001325879 aveo:HerculesMayTwoThousandSixteenLoanAgreementMember us-gaap:LoansPayableMember 2017-06-01 2017-06-30 0001325879 aveo:FinancialCovenantsMember aveo:HerculesMayTwoThousandSixteenLoanAgreementMember us-gaap:LoansPayableMember srt:MinimumMember 2017-06-30 0001325879 srt:MinimumMember us-gaap:LoansPayableMember 2020-06-30 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember 2017-12-31 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember 2017-12-01 2017-12-31 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:LoansPayableMember 2020-01-01 2020-06-30 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:LoansPayableMember 2017-12-31 0001325879 srt:MinimumMember aveo:FinancialCovenantsMember aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:LoansPayableMember 2017-12-31 0001325879 aveo:HerculesAmendedLoanAgreementMember us-gaap:LoansPayableMember 2017-12-31 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:LoansPayableMember 2017-12-01 2017-12-31 0001325879 aveo:JulyTwoThousandTwentyOneMember aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:LoansPayableMember 2017-12-31 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:LoansPayableMember srt:MinimumMember 2020-06-30 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:LoansPayableMember 2020-06-30 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:LoansPayableMember srt:MaximumMember 2020-06-30 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:LoansPayableMember 2018-12-31 0001325879 2018-09-30 0001325879 2018-06-30 0001325879 2019-10-31 0001325879 2019-09-30 0001325879 2019-08-31 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember 2018-11-30 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember 2018-11-01 2018-11-30 0001325879 aveo:JulyTwoThousandTwentyOneMember aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember 2018-11-30 0001325879 aveo:HerculesAmendedAndRestatedLoanAndSecurityAgreementMember 2020-06-30 0001325879 srt:MinimumMember 2020-02-19 0001325879 srt:BoardOfDirectorsChairmanMember 2020-02-13 2020-02-13 0001325879 srt:MaximumMember srt:BoardOfDirectorsChairmanMember 2020-02-13 2020-02-13 0001325879 srt:MinimumMember srt:BoardOfDirectorsChairmanMember 2020-02-13 2020-02-13 0001325879 2020-02-13 2020-02-13 0001325879 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001325879 us-gaap:CommonStockMember 2020-02-13 2020-02-13 0001325879 aveo:UnderwrittenPublicOfferingMember 2020-06-19 0001325879 us-gaap:OverAllotmentOptionMember 2020-06-19 0001325879 srt:MinimumMember 2020-06-19 0001325879 aveo:UnderwrittenPublicOfferingMember 2020-06-01 2020-06-19 aveo:Affiliate 0001325879 aveo:UnderwrittenPublicOfferingMember aveo:NewEnterpriseAssociatesAndAnotherStockholderMember 2020-06-19 0001325879 aveo:UnderwrittenPublicOfferingMember 2019-04-30 0001325879 aveo:UnderwrittenPublicOfferingMember aveo:OfferingWarrantsMember 2019-04-30 0001325879 us-gaap:OverAllotmentOptionMember aveo:OfferingWarrantsMember 2019-04-30 0001325879 srt:MinimumMember aveo:UnderwrittenPublicOfferingMember 2019-04-30 0001325879 srt:MinimumMember aveo:UnderwrittenPublicOfferingMember aveo:OfferingWarrantsMember 2019-04-30 0001325879 aveo:UnderwrittenPublicOfferingMember aveo:OfferingWarrantsMember 2019-04-01 2019-04-30 0001325879 aveo:UnderwrittenPublicOfferingMember 2019-04-01 2019-04-30 0001325879 aveo:NewEnterpriseAssociatesMember aveo:UnderwrittenPublicOfferingMember 2019-04-30 0001325879 aveo:NewEnterpriseAssociatesMember aveo:UnderwrittenPublicOfferingMember aveo:OfferingWarrantsMember 2019-04-30 0001325879 aveo:UnderwrittenPublicOfferingMember aveo:OfferingWarrantsMember 2020-06-30 0001325879 aveo:SVBLeerinkMember srt:MaximumMember 2018-02-28 0001325879 aveo:SVBLeerinkMember 2018-10-01 2018-12-31 0001325879 aveo:SVBLeerinkMember us-gaap:CommonStockMember 2019-02-01 2019-02-28 0001325879 aveo:SVBLeerinkMember 2020-06-30 0001325879 aveo:SettlementWarrantsMember 2018-07-16 0001325879 aveo:SettlementWarrantsMember 2018-07-15 2018-07-16 0001325879 aveo:SettlementWarrantsMember 2020-01-01 2020-06-30 0001325879 aveo:SettlementWarrantsMember 2018-07-14 2019-07-15 0001325879 srt:MaximumMember 2017-11-30 0001325879 us-gaap:PrivatePlacementMember aveo:PIPEWarrantsMember 2016-05-31 0001325879 us-gaap:PrivatePlacementMember aveo:PIPEWarrantsMember 2016-05-01 2016-05-31 0001325879 us-gaap:PrivatePlacementMember aveo:PIPEWarrantsMember aveo:DirectorAndExecutiveOfficerMember 2016-05-31 0001325879 us-gaap:PrivatePlacementMember aveo:PIPEWarrantsMember aveo:DirectorAndExecutiveOfficerMember 2016-05-01 2016-05-31 0001325879 us-gaap:PrivatePlacementMember aveo:PIPEWarrantsMember 2020-06-30 0001325879 us-gaap:PrivatePlacementMember aveo:PIPEWarrantsMember 2020-01-01 2020-06-30 0001325879 srt:MinimumMember us-gaap:EmployeeStockOptionMember aveo:ParticipantsWhoOwnLessThanTenPercentOfCombinedVotingPowerMember 2020-06-30 0001325879 srt:MaximumMember us-gaap:EmployeeStockOptionMember aveo:ParticipantsWhoOwnMoreThanTenPercentOfCombinedVotingPowerMember 2020-06-30 0001325879 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001325879 aveo:TwoThousandNineteenEquityIncentivePlanMember 2020-01-01 2020-06-30 0001325879 srt:MaximumMember aveo:TwoThousandNineteenEquityIncentivePlanMember 2020-06-30 0001325879 aveo:TwoThousandNineteenEquityIncentivePlanMember 2020-06-30 0001325879 aveo:EmployeeStockPurchasePlanTwentyTenMember 2020-06-30 0001325879 srt:MinimumMember 2020-04-01 2020-06-30 0001325879 srt:MinimumMember 2019-04-01 2019-06-30 0001325879 srt:MaximumMember 2020-04-01 2020-06-30 0001325879 srt:MaximumMember 2019-04-01 2019-06-30 0001325879 srt:MinimumMember 2019-01-01 2019-06-30 0001325879 srt:MaximumMember 2020-01-01 2020-06-30 0001325879 srt:MaximumMember 2019-01-01 2019-06-30 0001325879 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 aveo:LegalMatter 0001325879 us-gaap:PendingLitigationMember 2020-01-01 2020-06-30 0001325879 2017-12-26 2017-12-26 0001325879 aveo:SettlementWarrantsMember 2017-12-26 0001325879 aveo:SettlementWarrantsMember 2017-12-26 2017-12-26 0001325879 aveo:SettlementWarrantsMember 2018-02-01 2018-02-28 0001325879 aveo:SettlementWarrantsMember 2019-07-15 0001325879 2017-12-31 0001325879 2017-01-01 2017-12-31 0001325879 2018-06-29 0001325879 2016-03-28 2016-03-29 0001325879 2015-01-01 2015-12-31 0001325879 aveo:TwoThousandTwentyLoanAgreementMember us-gaap:SubsequentEventMember 2020-08-31 0001325879 aveo:TwoThousandTwentyLoanAgreementMember aveo:TrancheOneMember us-gaap:SubsequentEventMember 2020-08-31 0001325879 aveo:TwoThousandTwentyLoanAgreementMember us-gaap:SubsequentEventMember 2020-08-01 2020-08-31 0001325879 aveo:TrancheTwoMember srt:ScenarioForecastMember 2021-06-30 0001325879 aveo:TrancheThreeMember srt:ScenarioForecastMember 2021-07-02 0001325879 aveo:TrancheFourMember srt:ScenarioForecastMember 2022-06-30 0001325879 us-gaap:SubsequentEventMember 2020-08-01 2020-08-31 0001325879 us-gaap:SubsequentEventMember srt:MinimumMember aveo:TwoThousandTwentyLoanAgreementMember 2020-08-31 0001325879 us-gaap:SubsequentEventMember srt:MaximumMember aveo:TwoThousandTwentyLoanAgreementMember 2020-08-31 0001325879 2020-08-01 2020-08-31 0001325879 aveo:TwoThousandSeventeenLoanAgreementMember srt:ScenarioForecastMember 2021-07-01 2021-07-01 0001325879 us-gaap:SubsequentEventMember aveo:TwoThousandTwentyLoanAgreementMember srt:MinimumMember 2020-08-01 2020-08-31

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

 

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to                 .

Commission file number 001-34655

 

AVEO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

04-3581650

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

 

30 Winter Street, Boston, Massachusetts 02108

(Address of principal executive offices) (Zip Code)

(857400-0101

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

AVEO

Nasdaq Capital Market

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

  

Smaller reporting company

 

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Number of shares of the registrant’s Common Stock, $0.001 par value, outstanding on August 7, 2020: 25,808,315.

 

 

 


AVEO PHARMACEUTICALS, INC.

FORM 10-Q

FOR THE QUARTER ENDED JUNE 30, 2020

TABLE OF CONTENTS

 

 

 

 

Page

No.

 

 

 

 

PART I. FINANCIAL INFORMATION

 

 

 

 

 

Item 1.

 

Financial Statements

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019

3

 

 

 

 

 

 

Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2020 and 2019

4

 

 

 

 

 

 

Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2020 and 2019

5

 

 

 

 

 

 

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Three and Six Months Ended June 30, 2020 and 2019

6

 

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019

8

 

 

 

 

 

 

Notes to Condensed Consolidated Financial Statements

9

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

39

 

 

 

 

Item 4.

 

Controls and Procedures

57

 

 

 

 

PART II. OTHER INFORMATION

 

 

 

 

 

Item 1.

 

Legal Proceedings

58

 

 

 

 

Item 1A.

 

Risk Factors

58

 

 

 

 

Item 5.

 

Other Information

98

 

 

 

 

Item 6.

 

Exhibits

100

 

 

 

 

 

 

Signatures

101

 

2


AVEO PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets

(In thousands, except par value amounts)

(Unaudited)

 

 

 

June 30,

2020

 

 

December 31,

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

45,670

 

 

$

29,785

 

Marketable securities

 

 

25,779

 

 

 

17,960

 

Accounts receivable

 

 

1,208

 

 

 

1,631

 

Clinical trial retainers

 

 

524

 

 

 

589

 

Other prepaid expenses and other current assets

 

 

1,047

 

 

 

635

 

Total current assets

 

 

74,228

 

 

 

50,600

 

Property and equipment, net

 

 

96

 

 

 

 

Operating lease right-of-use asset

 

 

1,120

 

 

 

 

Other assets

 

 

158

 

 

 

 

Total assets

 

$

75,602

 

 

$

50,600

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,785

 

 

$

1,466

 

Accrued clinical trial costs and contract research

 

 

5,000

 

 

 

5,680

 

Other accrued liabilities

 

 

2,121

 

 

 

2,336

 

Operating lease liability

 

 

451

 

 

 

 

Loans payable, net of discount

 

 

10,193

 

 

 

9,569

 

Deferred revenue

 

 

1,974

 

 

 

1,974

 

Deferred research and development reimbursements

 

 

259

 

 

 

93

 

Total current liabilities

 

 

21,783

 

 

 

21,118

 

Loans payable, net of current portion and discount

 

 

940

 

 

 

6,197

 

Deferred revenue

 

 

1,565

 

 

 

2,552

 

PIPE Warrant liability (Note 7)

 

 

1,999

 

 

 

5,097

 

Operating lease liability, non-current

 

 

473

 

 

 

 

Other liabilities (Note 6)

 

 

790

 

 

 

790

 

Total liabilities

 

 

27,550

 

 

 

35,754

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $.001 par value: 5,000 shares authorized at June 30,

   2020 and December 31, 2019; no shares issued and outstanding at each of

   June 30, 2020 and December 31, 2019

 

 

 

 

 

 

Common stock, $.001 par value: 50,000 shares authorized at June 30,

   2020 and December 31, 2019; 25,808 shares issued and outstanding at

   June 30, 2020 and 16,081 issued and outstanding at December 31, 2019

 

 

26

 

 

 

16

 

Additional paid-in capital

 

 

649,335

 

 

 

600,451

 

Accumulated other comprehensive loss

 

 

(1

)

 

 

 

Accumulated deficit

 

 

(601,308

)

 

 

(585,621

)

Total stockholders’ equity

 

 

48,052

 

 

 

14,846

 

Total liabilities and stockholders’ equity

 

$

75,602

 

 

$

50,600

 

 

See accompanying notes.

 

3


AVEO PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

 

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration and licensing revenue

 

$

494

 

 

$

493

 

 

$

987

 

 

$

1,947

 

Partnership royalties

 

 

255

 

 

 

210

 

 

 

546

 

 

 

367

 

 

 

 

749

 

 

 

703

 

 

 

1,533

 

 

 

2,314

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

4,419

 

 

 

2,611

 

 

 

12,245

 

 

 

9,463

 

General and administrative

 

 

3,737

 

 

 

2,986

 

 

 

7,409

 

 

 

5,441

 

 

 

 

8,156

 

 

 

5,597

 

 

 

19,654

 

 

 

14,904

 

Loss from operations

 

 

(7,407

)

 

 

(4,894

)

 

 

(18,121

)

 

 

(12,590

)

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(349

)

 

 

(451

)

 

 

(664

)

 

 

(1,015

)

Change in fair value of PIPE Warrant liability

 

 

450

 

 

 

2,210

 

 

 

3,098

 

 

 

11,025

 

Other income (expense), net

 

 

101

 

 

 

1,759

 

 

 

2,434

 

 

 

10,010

 

Net loss

 

$

(7,306

)

 

$

(3,135

)

 

$

(15,687

)

 

$

(2,580

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share - basic and diluted

 

$

(0.42

)

 

$

(0.20

)

 

$

(0.94

)

 

$

(0.18

)

Weighted average number of common shares outstanding

 

 

17,364

 

 

 

15,902

 

 

 

16,722

 

 

 

14,574

 

 

See accompanying notes.

4


AVEO PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Net loss

 

$

(7,306

)

 

$

(3,135

)

 

$

(15,687

)

 

$

(2,580

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities

 

 

(1

)

 

 

 

 

 

(1

)

 

 

 

Comprehensive loss

 

$

(7,307

)

 

$

(3,135

)

 

$

(15,688

)

 

$

(2,580

)

 

See accompanying notes.

 

5


AVEO PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(In thousands)

(Unaudited)

 

 

 

Common Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Par Value

 

 

Additional

Paid-in

Capital

 

 

Accumulated

Other

Comprehensive

Income

 

 

Accumulated

Deficit

 

 

Total

Stockholders'

Equity

 

Balance at December 31, 2019

 

 

16,081

 

 

$

16

 

 

$

600,451

 

 

$

 

 

$

(585,621

)

 

$

14,846

 

Stock-based compensation expense

   related to equity- classified awards

 

 

 

 

 

 

 

 

543

 

 

 

 

 

 

 

 

 

543

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(8,381

)

 

 

(8,381

)

Balance at March 31, 2020

 

 

16,081

 

 

$

16

 

 

$

600,994

 

 

$

 

 

$

(594,002

)

 

$

7,008

 

Issuance of common stock in a public

   offering, excluding to related parties

   (net of issuance costs of $3.3 million)

 

 

5,221

 

 

 

5

 

 

 

24,106

 

 

 

 

 

 

 

 

 

24,111

 

Issuance of common stock in a public

   offering, to related parties

 

 

4,504

 

 

 

5

 

 

 

23,639

 

 

 

 

 

 

 

 

 

23,644

 

Stock-based compensation expense

   related to equity-classified awards

 

 

 

 

 

 

 

 

578

 

 

 

 

 

 

 

 

 

578

 

Issuance of common stock under

   employee stock purchase plan

 

 

2

 

 

 

 

 

 

18

 

 

 

 

 

 

 

 

 

18

 

Change in unrealized gain (loss) on

   investments

 

 

 

 

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

(1

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,306

)

 

 

(7,306

)

Balance at June 30, 2020

 

 

25,808

 

 

$

26

 

 

$

649,335

 

 

$

(1

)

 

$

(601,308

)

 

$

48,052

 

 

6


AVEO PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(In thousands)

(Unaudited)

 

 

 

Common Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Par Value

 

 

Additional

Paid-in

Capital

 

 

Accumulated

Other

Comprehensive

Income

 

 

Accumulated

Deficit

 

 

Total

Stockholders'

Equity (Deficit)

 

Balance at December 31, 2018

 

 

12,648

 

 

$

13

 

 

$

567,768

 

 

$

1

 

 

$

(595,009

)

 

$

(27,227

)

Issuance of common stock from the

   SVB Leerink sales agreement

   (net of issuance costs of $0.2

   million)

 

 

1,252

 

 

 

1

 

 

 

7,511

 

 

 

 

 

 

 

 

 

7,512

 

Stock-based compensation expense

   related to equity-classified awards

 

 

 

 

 

 

 

 

584

 

 

 

 

 

 

 

 

 

584

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

555

 

 

 

555

 

Balance at March 31, 2019

 

 

13,900

 

 

$

14

 

 

$

575,863

 

 

$

1

 

 

$

(594,454

)

 

$

(18,576

)

Issuance of common stock and

   warrants in a public offering,

   excluding to related parties

   (net of issuance costs of

   $2.3 million)

 

 

1,739

 

 

 

2

 

 

 

17,765

 

 

 

 

 

 

 

 

 

17,767

 

Issuance of common stock and

   warrants in a public offering,

   to related parties

 

 

435

 

 

 

 

 

 

5,000

 

 

 

 

 

 

 

 

 

5,000

 

Stock-based compensation expense

   related to equity-classified awards

 

 

 

 

 

 

 

 

584

 

 

 

 

 

 

 

 

 

584

 

Exercise of stock options

 

 

 

 

 

 

 

 

3

 

 

 

 

 

 

 

 

 

3

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3,135

)

 

 

(3,135

)

Balance at June 30, 2019

 

 

16,074

 

 

$

16

 

 

$

599,215

 

 

$

1

 

 

$

(597,589

)

 

$

1,643

 

 

7


AVEO PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Six Months Ended

June 30,

 

 

 

2020

 

 

2019

 

Operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(15,687

)

 

$

(2,580

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and Amortization

 

 

4

 

 

 

 

Stock-based compensation

 

 

1,121

 

 

 

1,168

 

Non-cash interest expense

 

 

200

 

 

 

311

 

Non-cash change in fair value of PIPE Warrant liability

 

 

(3,098

)

 

 

(11,025

)

Amortization of premium and discount on investments

 

 

(81

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

423

 

 

 

2,415

 

Prepaid expenses and other current assets

 

 

(347

)

 

 

 

Operating lease right-of-use asset

 

 

(1,278

)

 

 

(337

)

Accounts payable

 

 

319

 

 

 

(1,536

)

Accrued contract research

 

 

(680

)

 

 

(1,546

)

Other accrued liabilities

 

 

(215

)

 

 

(1,143

)

Other current liabilities

 

 

451

 

 

 

 

Deferred revenue

 

 

(987

)

 

 

53

 

Deferred research and development reimbursements